Reto Wittwer
Direttore Finanziario/CFO presso Cardiorentis AG
Posizioni attive di Reto Wittwer
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Cardiorentis AG
 Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Direttore Finanziario/CFO | 10/01/2016 | - |
DiNAQOR AG
 DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Direttore/Membro del Consiglio | - | - |
| Direttore Finanziario/CFO | - | - |
Storia della carriera di Reto Wittwer
Formazione di Reto Wittwer
| University of Zurich | Graduate Degree |
| University of St. Gallen | Graduate Degree |
Statistiche
Distribuzione geografica
| Svizzera | 5 |
Posizioni
| Director of Finance/CFO | 2 |
| Graduate Degree | 2 |
| Director/Board Member | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Cardiorentis AG
Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Health Technology |
DiNAQOR AG
DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Health Technology |
- Borsa valori
- Insiders
- Reto Wittwer
- Esperienza
